Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece.

AbstractIbrutinib (IB) revealed high efficacy and safety profile in phase 2/3 chronic lymphocytic clinical trials. Emerging real-world-data shows similar response and survival, but higher discontin...